Blade Therapeutics, a South San Francisco, CA-based biopharmaceutical company developing medicines for the treatment of fibrotic disease, raised up to $45m in Series B financing.
The round was led by Deerfield Management with participation from Pfizer Venture Investments, Novartis Institutes for Biomedical Research and Bristol-Myers Squibb and existing investors MPM Capital and Osage University Partners. In conjunction with the funding, William Slattery and Cameron Wheeler, Ph.D. from Deerfield Management and Elaine Jones, Ph.D. from Pfizer Venture Investments, joined Blade’s Board of Directors.
The company intends to use the funds to advance the selection and development of lead molecules designed to modify the pathobiology of fibrotic diseases.
Founded on research from the laboratory of Harry (Hal) Dietz, M.D., Victor A. McKusick Professor of Genetics and Medicine, Johns Hopkins University and a Howard Hughes Medical Investigator, and led by Chief Executive Officer Wendye Robbins, M.D., Blade Therapeutics is exploiting novel target biology to halt the progression of fibrotic disease via novel therapies that can modify their course.